NCT06671548 2026-02-02
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
Clinical Trials
40 trialsNCT07378098 2026-01-30
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
JW Pharmaceutical
Phase 3 Recruiting
NCT04756037 2026-01-08
SERENE
Sumitomo Pharma Switzerland GmbH
Phase 3 Active not recruiting
NCT05445167 2025-11-25
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT05862272 2025-08-06
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma Switzerland GmbH
Phase 3 Recruiting
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT03271489 2025-07-22
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT05440383 2025-03-14
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03240523 2024-10-18
ASTEROID 5
Bayer
Phase 3 Terminated
NCT03751124 2024-06-25
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03400943 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Bayer
Phase 3 Terminated
NCT05620355 2023-03-21
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
Bio Genuine (Shanghai) Biotech Co., Ltd.
Phase 3 Unknown
NCT03476928 2022-07-08
ASTEROID 8
Bayer
Phase 3 Terminated
NCT03400956 2022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Bayer
Phase 3 Terminated
NCT03103087 2022-04-20
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT02691494 2021-07-13
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
AbbVie
Phase 3 Completed
NCT02925494 2021-07-13
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
AbbVie
Phase 3 Completed
NCT03070951 2021-03-05
PRIMROSE 2
ObsEva SA
Phase 3 Completed
NCT02654054 2020-06-29
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT03699176 2020-01-18
ASTEROID 7
Bayer
Phase 3 Withdrawn
NCT02147197 2019-04-30
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Allergan
Phase 3 Completed
NCT02655224 2019-03-22
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Takeda
Phase 3 Completed
NCT00295217 2018-12-20
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
InSightec
Phase 3 Completed
NCT01156857 2016-01-15
PEARLIII
PregLem SA
Phase 3 Completed
NCT01252069 2016-01-13
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)
PregLem SA
Phase 3 Completed
NCT01642472 2016-01-08
PEARLext2
PregLem SA
Phase 3 Completed
NCT00737282 2014-08-21
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00853567 2014-08-21
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01069120 2014-08-21
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00874302 2014-06-27
Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms
Repros Therapeutics Inc.
Phase 3 Withdrawn
NCT01553123 2013-02-07
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
Watson Pharmaceuticals
Phase 3 Withdrawn
NCT01064960 2012-12-04
Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner
Philips Healthcare
Phase 3 Completed
NCT01141062 2012-12-04
HIFU
Philips Healthcare
Phase 3 Completed
NCT00152256 2008-05-29
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
Abbott
Phase 3 Completed
NCT00152269 2008-05-29
Treatment of Uterine Fibroids With Asoprisnil(J867)
Abbott
Phase 3 Completed
NCT00156195 2008-05-29
Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids
Abbott
Phase 3 Completed
NCT00156208 2008-05-29
Safety of Treatment of Uterine Fibroids With Asoprisnil
Abbott
Phase 3 Completed
NCT00160381 2008-05-29
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
Abbott
Phase 3 Completed
NCT00156156 2008-05-28
Study of Asoprisnil in the Treatment of Uterine Fibroids.
Abbott
Phase 3 Completed